Trials / Completed
CompletedNCT01140217
Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,659 (actual)
- Sponsor
- Watson Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.
Detailed description
An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Norethindrone Acetate | Norethindrone Acetate Transdermal Delivery System |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-06-09
- Last updated
- 2013-09-19
Locations
53 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01140217. Inclusion in this directory is not an endorsement.